AIM ImmunoTech Inc (NYSE:AIM) CEO Tom Equels and Chief Scientific Officer David Strayer joined Proactive to discuss positive data from its Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer.
The study has been published in the American Association for Cancer Research publication, Clinical Cancer Research under the title, 'Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity'.